Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primarily biliary excretion, allowing use in renal impairment without dose adjustment. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. ## Adult Dosing * **Standard Dose:** 5 mg orally once daily. * **Maximum Dose:** 5 mg daily. ## Pediatric Dosing * **Safety/Efficacy:** Not established for pediatric populations (<18 years). Use is not recommended. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required (regardless of severity, including ESRD). * **Hepatic Impairment:** No dose adjustment required. * **Concomitant use with Insulin/Secretagogues:** Consider a lower dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. ## Contraindications * History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to linagliptin. ## Adverse Effects * **Common:** Nasopharyngitis, diarrhea, arthralgia. * **Serious:** Acute pancreatitis (discontinue if symptoms occur), severe/disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin exposure. Increased monitoring of glycemic control or use of an alternative agent may be necessary. ## Monitoring * **Glycemic Control:** HbA1c (typically every 3–6 months). * **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or erosions). ## Clinical Pearls * Linagliptin is weight-neutral and has a low intrinsic risk of hypoglycemia when used as monotherapy. * It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. * Unlike other DPP-4 inhibitors, no renal dosing adjustment is required, making it a preferred choice for patients with significant chronic kidney disease. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines and prescribing information change frequently. Always consult the latest version of the manufacturer’s package insert, institutional protocols, or clinical decision support tools before prescribing or administering medication.*